On January 20, 2026, Jonathan Harris, President and Chief Executive Officer of Owlet, Inc. (NASDAQ: OWLT), completed the sale of 2,311 shares of Owlet common stock at a price of $13.33 per share. The total value of this transaction amounted to $30,805.
The insider transaction was disclosed via a Form 4 filing submitted to the Securities and Exchange Commission. Subsequent to this sale, Harris retains direct ownership of 264,396 shares of Owlet stock.
Details within the SEC filing clarify that the shares sold were part of a non-discretionary event, whereby automatic sales were executed to satisfy tax obligations and associated fees linked to the vesting and settlement of restricted stock units held by Harris.
The filing was officially signed on behalf of Jonathan Harris by Kirsten O’Donnell, acting as Attorney-in-Fact, on January 22, 2026.
Parallel to these insider sales, Owlet has been actively developing its business footprint. Most notably, the company announced a strategic partnership with 1 Natural Way, aimed at broadening insurance-covered access to Owlet's FDA-cleared BabySat infant pulse oximeter. This initiative is designed to facilitate availability through insurance programs including Medicaid and TRICARE.
Moreover, Owlet has expanded its Owlet360 subscription service into the United Kingdom and Ireland. This service complements its Dream Sock and Dream Sight devices by offering customized insights into infant sleep patterns and health metrics, while maintaining core features at no additional cost.
The company also launched its Dream Sock infant health monitoring product in Australia and New Zealand following approval from the Therapeutic Goods Administration of Australia. This device actively monitors key vital signs such as pulse rate and oxygen saturation, delivering real-time data to parents.
From the perspective of financial analysts, Owlet has garnered positive attention. TD Cowen commenced coverage with a Buy rating and set a price target increase to $19.00, while William Blair initiated coverage with an Outperform rating, highlighting the company's promising growth potential.
These recent developments collectively illustrate Owlet’s concerted efforts to extend its market presence and enhance its offerings in the pediatric health monitoring sector.